Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis
- PMID: 36695545
- DOI: 10.5507/bp.2023.002
Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis
Abstract
Aim: The aim of this study was to identify whether NfL and CXCL13 cerebrospinal fluid (CSF) concentrations at diagnostic lumbar puncture can predict the course of multiple sclerosis (MS) in terms of relapses, higher expanded disability status scale (EDSS) and magnetic resonance imaging (MRI) activity.
Methods: We conducted a single-centre prospective observational cohort study at the MS center, University Hospital Ostrava, Czech Republic. CSF NfL (cNfL) and CXCL13 concentrations were examined (ELISA method) in patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) at the time of diagnostic lumbar puncture.
Results: A total of 44 patients with CIS or early RRMS were enrolled, 31 (70.5%) of whom were women. The median age at the time of CSF sampling was 31.21 years (IQR 25.43-39.32), and the follow-up period was 54.6 months (IQR 44.03-59.48). In the simple and multiple logistic regression models, CXCL13 levels did not predict relapses, MRI activity or EDSS > 2.5. Similarly, cNfL concentrations did not predict relapses or MRI activity in either model. In the multiple regression, higher cNfL levels were associated with reaching EDSS > 2.5 (odds ratio [OR] 1.002, 95% confidence interval [CI] 1.000 to 1.003).
Conclusions: Our data did not confirm cNfL and/or CXCL13 CSF levels were predictive factors for disease activity such as relapses and MRI activity at the time of diagnostic lumbar puncture in patients with RRMS. While cNfL CSF levels predicted higher disability only after adjustment for other known risk factors, elevated CSF CXCL13 did not predict higher disability at all.
Keywords: CXCL13; biomarkers; clinical course; multiple sclerosis; neurofilament light chain.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
-
Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity.Mult Scler Relat Disord. 2025 Feb;94:106268. doi: 10.1016/j.msard.2025.106268. Epub 2025 Jan 11. Mult Scler Relat Disord. 2025. PMID: 39832432
-
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.Mult Scler. 2022 May;28(6):872-884. doi: 10.1177/13524585211039104. Epub 2021 Aug 16. Mult Scler. 2022. PMID: 34392718 Free PMC article.
-
Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.Hell J Nucl Med. 2019 Sep-Dec;22 Suppl 2:113-121. Hell J Nucl Med. 2019. PMID: 31802051
-
Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.PLoS One. 2022 Sep 14;17(9):e0274565. doi: 10.1371/journal.pone.0274565. eCollection 2022. PLoS One. 2022. PMID: 36103562 Free PMC article.
-
Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1059-1067. doi: 10.1136/jnnp-2018-319190. Epub 2019 May 23. J Neurol Neurosurg Psychiatry. 2019. PMID: 31123141 Free PMC article.
Cited by
-
Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis.Biomedicines. 2024 Dec 27;13(1):40. doi: 10.3390/biomedicines13010040. Biomedicines. 2024. PMID: 39857624 Free PMC article.
-
Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights.Ann Neurol. 2024 Oct;96(4):704-714. doi: 10.1002/ana.27024. Epub 2024 Jul 19. Ann Neurol. 2024. PMID: 39031103
-
Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review.Front Mol Neurosci. 2023 Sep 12;16:1210091. doi: 10.3389/fnmol.2023.1210091. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37781097 Free PMC article. Review.
-
Chitinase-3-Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers.Brain Behav. 2025 Jun;15(6):e70619. doi: 10.1002/brb3.70619. Brain Behav. 2025. PMID: 40495463 Free PMC article.
-
No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules. 2025 Jan 6;15(1):68. doi: 10.3390/biom15010068. Biomolecules. 2025. PMID: 39858462 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical